Tag: gout
-
Gout Rise Explained: Simple Lifestyle to Lower Uric Acid
Why Gout Cases Are Rising Gout, a painful form of inflammatory arthritis, is affecting more people around the world. While once seen mainly in older adults, rising prevalence is being reported in younger age groups as well. Several factors contribute to this trend, including aging populations, shifts in diet, and the global rise in obesity.…
-
CRISPR Brings Back Ancient Gene That Could Cut Gout and Fatty Liver Risk
Rewriting a Missing Chapter in Human Biology In a surprising turn for genetic science, researchers using CRISPR gene-editing tools have revived a gene that disappeared from the human lineage millions of years ago. The restored gene appears to play a role in regulating uric acid production and lipid metabolism, two factors closely tied to gout…
-
CRISPR Resurrects Ancient Gene to Fight Gout and Fatty Liver
CRISPR Brings Back an Ancient Gene With Modern Implications A recent report in Scientific Reports unveils a bold genetic experiment: scientists used CRISPR gene-editing tools to revive a gene that vanished from the human lineage millions of years ago. The revived gene appears to modulate purine metabolism and uric acid production, leading to lower uric…
-
CRISPR Restores Ancient Gene to Cut Uric Acid and Fight Gout and Fatty Liver
Introduction: A bold leap from ancient DNA to modern health In a striking demonstration of CRISPR gene-editing tools, researchers have resurrected an ancient human gene that disappeared from the genome millions of years ago. The restored gene, when expressed in a controlled laboratory setting, lowered uric acid levels and showed promising indications for reducing risks…
-
Sobi to Unveil One-Year Pegcetacoplan Data for C3G, IC-MPGN and NASP at ASN Kidney Week 2025
Overview: Sobi to Share New Pegcetacoplan Data at ASN Kidney Week 2025 Sobi, a global biopharmaceutical company focused on rare diseases, has announced that new data on pegcetacoplan will be presented at ASN Kidney Week 2025, taking place from November 5–9. The presentations will explore one-year efficacy data for pegcetacoplan in C3 glomerulopathy (C3G) and…